Efficacy and safety of the medications of first line treatment (artesunate+amodiaquine) and second line treatment (artemether+lumefantrine) for the treatment of uncomplicated Plasmodium falciparum in Malabo, Bata and Ebibey, Equatorial Guinee

Ministry of Public Health of Equatorial Guinea0 个研究点目标入组 528 人开始时间: 2017年3月28日最近更新: 2019年11月11日

适应症

试验速览

暂无简介。

•1. age from 6 to 59 months;
•2. mono-infection with P. falciparum detected by microscopy;
•3. parasitaemia of 1000–200,000/microliter asexual forms;
•4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h
•5. ability to swallow oral medication;
•6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
•7. informed consent from the patient or parent/ guardian of children.

•1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
•2. weight under 5 kg;
•4. mixed or mono-infection with another Plasmodium species detected by microscopy;
•5. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference below 115 mm)
•6. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
•7. regular medication, which may interfere with antimalarial pharmacokinetics;
•8. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s).

发起方

Ministry of Public Health of Equatorial Guinea